TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial

Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy

(2016) Ronnie P. Kasirye et al.   AIDS

Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial

(2016) Christina S. Polyak et al.   PLOS MEDICINE

Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design

(2015) Zacchaeus Anywaine et al.   Contemporary Clinical Trials

HIV-Infected Ugandan Adults Taking Antiretroviral Therapy With CD4 Counts >200 Cells/ L Who Discontinue Cotrimoxazole Prophylaxis Have Increased Risk of Malaria and Diarrhea

(2012) J. D. Campbell et al.   CLINICAL INFECTIOUS DISEASES

Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count

(2010)   CLINICAL INFECTIOUS DISEASES

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

(2010) AS Walker et al.   LANCET

Response to Zidovudine/Didanosine-Containing Combination Antiretroviral Therapy Among HIV-1 Subtype C-Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical Trial

(2009) Hermann Bussmann et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES